U.S. markets close in 1 hour 50 minutes

Compugen Ltd. (CGEN)

NasdaqCM - NasdaqCM Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
2.5709+0.0309 (+1.22%)
A partir del 02:04PM EDT. Mercado abierto.

Compugen Ltd.

Azrieli Center
Building D 26 Harokmim Street
Holon 5885849
Israel
972 3 765 8585
https://cgen.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo68

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Anat Cohen-Dayag Ph.D.CEO, President & Director796.52kN/D1967
Dr. Zurit Levine Ph.D.Senior Vice President of Technology Innovation345.7kN/D1968
Dr. Pierre Ferre Ph.D.Vice President of Preclinical Development415.1kN/D1977
Mr. Alberto SessaChief Financial OfficerN/DN/D1962
Dr. Eran Ophir Ph.D.Chief Scientific OfficerN/DN/D1978
Ms. Yvonne NaughtonHead of Investor Relations & Corporate CommunicationsN/DN/DN/D
Mr. Eran Ben DorGeneral Counsel & Corporate SecretaryN/DN/DN/D
Ms. Dorit AmitayVice President of Human ResourcesN/DN/D1968
Dr. Yaron Turpaz M.B.A., Ph.D.Senior VP & Senior Advisor of Data and Informatics SolutionsN/DN/D1971
Rivka SchwartzVice President Research and DiscoveryN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Gestión corporativa

La calificación ISS Governance QuickScore de Compugen Ltd. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.